Unity Biotechnology has reported outcomes from its randomised Phase IIb ASPIRE study of intravitreal UBX1325 for diabetic macular oedema. The post Unity reports topline outcomes from trial of diabetic macular oedema therapy appeared first on Clinical Trials Arena.